The lawsuit, filed by the Rosen Law Firm, claims that Hims & Hers misled shareholders by failing to disclose that it shared sensitive consumer health information with third-party advertising platforms. Furthermore, the complaint alleges the company charged customers for prescriptions almost immediately after they submitted intake forms, contradicting claims that patients would first consult with medical providers to determine appropriate treatments. These practices reportedly invited regulatory scrutiny and potential financial penalties, causing investor losses when the details became public.

Those interested in joining the action may do so through the Rosen Law Firm, which operates on a contingency fee basis. While a lawsuit is already active, no class has been formally certified, meaning investors are not currently represented by counsel unless they retain their own. Participation as a lead plaintiff is not required to share in a potential future recovery, but those wishing to take an active role in directing the litigation must submit their motion to the court by the November deadline.